Mylotarg (Wyeth)
Mylotarg (Wyeth) - General Information
Recombinant humanized IgG4, kappa antibody conjugated with a cytotoxic antitumor antibiotic, calicheamicin, isolated from fermentation of a bacterium, Micromonospora echinospora ssp. calichensis. The antibody portion of Mylotarg binds specifically to the CD33 antigen, The anti-CD33 hP67.6 antibody is produced by mammalian cell suspension culture using a myeloma NS0 cell line.
Pharmacology of Mylotarg (Wyeth)
Used for the treatment of acute myeloid leukemia (AML), mylotarg binds to the CD33 antigen, which is expressed on the surface of leukemic cells in more than 80% of patients with AML. The CD33 antigen is not expressed on pluripotent hematopoietic stem cells or nonhematopoietic cells. This gives mylotarg the selectivity needed to target leukemic cells.
Mylotarg (Wyeth) for patients
Mylotarg (Wyeth) Interactions
There have been no formal drug-interaction studies performed with Mylotarg. The potential for drug-drug interaction with drugs affected by cytochrome P450 enzymes may not be ruled out.
Laboratory Test Interactions
Mylotarg is not known to interfere with any routine diagnostic tests.
Mylotarg (Wyeth) Contraindications
Mylotarg is contraindicated in patients with a known hypersensitivity to gemtuzumab ozogamicin or any of its components: anti-CD33 antibody (hP67.6), calicheamicin derivatives, or inactive ingredients.
Additional information about Mylotarg (Wyeth)
Mylotarg (Wyeth) Indication: For treatment of acute myeloid leukemia
Mechanism Of Action: Mylotarg is directed against the CD33 antigen expressed by hematopoietic cells. Binding of the anti-CD33 antibody portion of Mylotarg with the CD33 antigen results in the formation of a complex that is internalized. Upon internalization, the calicheamicin derivative is released inside the lysosomes of the myeloid cell. The released calicheamicin derivative binds to DNA in the minor groove resulting in DNA double strand breaks and cell death.
Drug Interactions: Not Available
Food Interactions: Not Available
Generic Name: Gemtuzumab ozogamicin
Synonyms: Mylotarg; anti-CD33
Drug Category: Antineoplastic Agents
Drug Type: Biotech; Approved
Other Brand Names containing Gemtuzumab ozogamicin: Mylotarg (Wyeth);
Absorption: Not Available
Toxicity (Overdose): Not Available
Protein Binding: Not Available
Biotransformation: Most likely removed by opsonization via the reticuloendothelial system.
Half Life: Not Available
Dosage Forms of Mylotarg (Wyeth): Injection, powder, lyophilized, for solution Intravenous
Chemical IUPAC Name: Humanized chimeric anti-CD33 antibody
Chemical Formula: Not Available
Gemtuzumab ozogamicin on Wikipedia: https://en.wikipedia.org/wiki/Gemtuzumab_ozogamicin
Organisms Affected: Humans and other mammals
